Fast Track

A Gail-model 5-year estimate of 1.66% or higher denotes a high risk of breast cancer

In the Breast Cancer Prevention Trial, tamoxifen reduced the risk of invasive breast cancer by 49% and the risk of noninvasive cancer by 50%

With tamoxifen, serious adverse events do not occur at the same magnitude in women younger than 50 years that they do in women 50 and older

Raloxifene does not cause endometrial hyperplasia or cancer and is not associated with vaginal bleeding or increased endometrial thickness

Both raloxifene and tamoxifen have consistently been associated with a twofold to threefold increase in the risk of thromboembolic events, compared with placebo